Get the Stockscreener App
54.06
0.11%
-0.06
Biomarin Pharmaceutical Inc stock is traded at $54.06, with a volume of 1.97M.
It is down -0.11% in the last 24 hours and down -5.49% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$54.12
Open:
$54.15
24h Volume:
1.97M
Relative Volume:
0.97
Market Cap:
$10.45B
Revenue:
$3.24B
Net Income/Loss:
$348.90M
P/E Ratio:
30.34
EPS:
1.7817
Net Cash Flow:
$717.02M
1W Performance:
+0.00%
1M Performance:
-5.49%
6M Performance:
+5.05%
1Y Performance:
-9.63%
1-Day Range:
$53.53
$54.55
1-Week Range:
$52.65
$57.44
52-Week Range:
$50.76
$66.28
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
54.06 | 10.45B | 3.24B | 348.90M | 717.02M | 1.7817 |
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 109.09B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
714.89 | 74.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
782.17 | 48.64B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.05 | 39.39B | 4.29B | 577.22M | 641.34M | 4.2086 |
ONC
Beone Medicines Ltd Adr
|
312.12 | 32.38B | 5.36B | 287.73M | 924.18M | 2.5229 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-27-26 | Resumed | Morgan Stanley | Overweight |
| Jan-28-26 | Resumed | Barclays | Overweight |
| Jan-20-26 | Upgrade | Canaccord Genuity | Hold → Buy |
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
BioMarin outlines $3.825B-$3.925B 2026 revenue outlook driven by Amicus integration and 20% growth target - MSN
BioMarin profit falls 43% on higher drug manufacturing and acquisition costs - The Press Democrat
BioMarin Pharmaceutical Price Target Raised to $116.00/Share From $104.00 by Canaccord Genuity - Moomoo
BMRN (NASDAQ) Form 144: 3,281 shares via Fidelity on 05/07/2026 - Stock Titan
Is BioMarin Pharmaceutical Inc. (BMRN) One of the Top Cheap Stocks to Buy With the Biggest Upside Potential? - Insider Monkey
Canaccord raises BioMarin stock price target to $116 on earnings beat - Investing.com UK
BioMarin: 'Strong Buy' On VOXZOGO Expansion And Amicus Acquisition (NASDAQ:BMRN) - Seeking Alpha
Top 5 Cheap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Is BioMarin Pharmaceutical (BMRN) Pricing Reflect Its Rare Disease Growth And Voxzogo Prospects - Yahoo Finance
BioMarin Q1 Earnings Miss, Sales Beat, '26 Revenue Guidance Raised - sharewise.com
MSN Money - MSN
BioMarin (NASDAQ: BMRN) Q1 profit drops as $4.8B Amicus acquisition ramps - Stock Titan
BioMarin Pharmaceutical 1Q 2026: Revenue $766.2M, EPS $0.54— 10-Q Summary - TradingView
BioMarin Pharmaceutical Q1 Revenue Beat Backed by Voxzogo Strength, Diversified Portfolio, Wedbush Says - marketscreener.com
BioMarin Enters 'Transition Year' as Enzyme Portfolio Expands After Amicus Deal, Morgan Stanley Says - marketscreener.com
Bernstein SocGen lowers BioMarin stock price target on guidance update By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2026 Earnings Call Transcript - Insider Monkey
BioMarin to buy rare disease drugmaker Amicus Therapeutics for $4.8B - MSN
Bernstein SocGen lowers BioMarin stock price target on guidance update - Investing.com
BioMarin Pharmaceutical Q1 2026: $0.76 EPS Falls Short — Deep Dive - AlphaStreet
Evercore ISI raises BioMarin stock price target on valuation gap By Investing.com - Investing.com Nigeria
Evercore ISI raises BioMarin stock price target on valuation gap - Investing.com
BMRN Q1 Deep Dive: Amicus Acquisition, Pipeline Milestones, and Order Dynamics Shape Outlook - TradingView
BioMarin Boosts 2026 Outlook After Amicus Deal - TipRanks
BioMarin Q1 2026 Earnings Preview: Revenue Growth Expected to SlowNews and Statistics - IndexBox
BioMarin Pharmaceutical Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Compared to Estimates, BioMarin (BMRN) Q1 Earnings: A Look at Key Metrics - Yahoo Finance
BMRN: Amicus acquisition accelerates 2026 revenue growth outlook to 20% with robust Q1 demand - TradingView
BioMarin (BMRN) Q1 2026 Earnings Transcript - AOL.com
BMRN: Amicus acquisition drives 20% 2026 revenue growth outlook and portfolio expansion - TradingView
BioMarin Q1 2026 slides: revenue beats forecast, eyes 20% growth - Investing.com
BioMarin Pharmaceutical Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: BioMarin Q1 2026 beats EPS forecasts, stock dips slightly - Investing.com
Transcript: Biomarin Pharmaceutical Q1 2026 Earnings Conference Call - Benzinga
BioMarin Pharmaceutical (BMRN) Q1 Earnings Lag Estimates - Yahoo Finance
BioMarin Pharmaceutical Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:BMRN) 2026-05-04 - Seeking Alpha
BioMarin beats estimates, raises guidance on Amicus deal By Investing.com - Investing.com South Africa
BioMarin Pharmaceutical Inc (NASDAQ:BMRN) Q1 Earnings Miss Masked by Raised 2026 Guidance - ChartMill
BioMarin Pharmaceutical Q1 Non-GAAP Earnings Fall, Revenue Rises; 2026 Guidance Revised - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Reports Q1 Revenue $766.2M, vs. FactSet Est of $752.2M - marketscreener.com
BioMarin beats estimates, raises guidance on Amicus deal - Investing.com
(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Revenue Range $3.83B$3.93B - marketscreener.com
BioMarin: Q1 Earnings Snapshot - marketscreener.com
(BMRN) BioMarin Pharmaceutical Expects Full Year 2026 Adjusted EPS Range $4.85$5.05 - marketscreener.com
Earnings Flash (BMRN) BioMarin Pharmaceutical Inc. Posts Q1 Adjusted EPS $0.76 per Share, vs. FactSet Est of $0.91 - marketscreener.com
BioMarin Pharmaceutical (NASDAQ:BMRN) Misses Q1 CY2026 Revenue Estimates - Yahoo Finance
BMRN: Q1 2026 revenue up 3% Y/Y; FY'26 guidance raised post-Amicus acquisition - TradingView
BioMarin (NASDAQ: BMRN) raises 2026 sales view following Amicus deal - Stock Titan
BioMarin Pharmaceutical Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
BioMarin Pharmaceutical 1Q Net $105.5M >BMRN - Moomoo
BioMarin Pharmaceutical (BMRN) Stock Analysis: Uncovering A 66.79% Upside Potential - DirectorsTalk Interviews
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
11.97%
3.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):